Events
UPCOMING EVENTS PAST EVENTS
Search Results for: 68
FAQs
What is Theriva™ Biologics stock symbol? Our stock is traded on the NYSE American under the symbol TOVX. Can I buy stock directly from Theriva Biologics? No, you will need to contact a licensed stock broker or use an online trading account. Where is Theriva Biologics located? 9605 Medical Center Dr.Suite 270Rockville, MD 20850 When
Corporate Governance
Governance Documents Code of Conduct Code of Ethics for Financial Management Audit Committee Charter Compensation Committee Charter Nominations Committee Charter Other Links View Our Leadership Team View Our Board of Directors Committee Composition Audit Committee Compensation Committee Nominations Committee Jeffrey Wolf, JD Chair Member Member Jeffrey J. Kraws Member Chair Member John Monahan, Ph.D. Member
Corporate Governance Read More »
Stock Information
Theriva™ Biologics (NYSE AMERICAN: TOVX) Analyst Coverage Firm Analyst A.G.P. / Alliance Global Partners James Molloy Maxim Group Jason McCarthy, Ph.D
Investors
About Theriva™ Biologics, Inc. Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for
Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock
ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D
Synthetic Biologics Announces Reverse Stock Split
ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share
Synthetic Biologics Announces Reverse Stock Split Read More »